Brian L. Strom
Brian L. Strom | |
|---|---|
 Chancellor Brian L. Strom | |
| 1st Chancellor of Rutgers Biomedical Health and Sciences
Executive Vice President for Health Affairs
| |
| Assumed office December 2, 2013 | |
| Preceded by | Office Established |
| Personal details | |
| Born | December 8, 1949 New York, New York |
| Spouse | Elaine Strom |
| Children | Shayna Jordan |
| Alma mater | Yale University (B.S.) The Johns Hopkins University School of Medicine (M.D.) University of California, Berkeley (M.P.H.) |
| Website | http://rbhs.rutgers.edu/chancellor_info.shtml |
Brian L. Strom, MD, MPH (born December 8, 1949) - As Inaugural Chancellor of Rutgers Biomedical and Health Sciences and the Executive Vice President for Health Affairs at Rutgers University, Dr. Strom has spearheaded the creation of an interprofessional faculty practice group; established a formal partnership with RWJBarnabas Health to create the New Jersey’s largest and most comprehensive academic health system; and led a major recruitment drive to bring the nation’s most talented biomedical researchers and clinicians to Rutgers. Prior to joining Rutgers, Dr. Strom was the Executive Vice Dean for Institutional Affairs, Founding Chair of the Department of Biostatistics and Epidemiology, Founding Director of the Center for Clinical Epidemiology and Biostatistics, and Founding Director of the Graduate Program in Epidemiology and Biostatistics, at the Perelman School of Medicine of the University of Pennsylvania. In addition to writing more than 650 papers and 15 books, he has been principal investigator for more than 275 grants, including over $115 million in direct costs alone. He was honored as one of the Best Doctors in America, for each of his last eight years at Penn.
Early life and education
Brian Leslie Strom was born on December 8, 1949, in New York City. He grew up Floral Park, New York and attended Martin Van Buren High School in Queens Village. As an undergraduate, Strom attended Yale University, where he earned his Bachelor of Science degree in molecular biophysics and biochemistry. After graduating, he received his Doctor of Medicine at The Johns Hopkins University School of Medicine. Following his medical internship and residency in Internal Medicine at University of California, San Francisco, he earned a Master of Public Health degree in Epidemiology from the University of California, Berkeley while concurrently serving as an National Institutes of Health Research Fellow in Clinical Pharmacology at the University of California, San Francisco.
Career
Brian L. Strom, MD, MPH is the Inaugural Chancellor of Rutgers Biomedical and Health Sciences (RBHS) and the Executive Vice President for Health Affairs at Rutgers University. RBHS is comprised of eight schools and seven major centers/institutes, and includes academic, patient care, and research facilities. These are most of the units of the former University of Medicine and Dentistry of New Jersey (UMDNJ), now dissolved, several Rutgers University units with health-related missions, and two research units historically co-managed by Rutgers and UMDNJ. The integration of these entities is designed to create a single organization that will lead to new models for clinical care and community service, educate the next generation of health care providers utilizing health care team approaches, and conduct research. Dr. Strom was formerly the Executive Vice Dean for Institutional Affairs, Founding Chair of the Department of Biostatistics and Epidemiology, Founding Director of the Center for Clinical Epidemiology and Biostatistics, and Founding Director of the Graduate Program in Epidemiology and Biostatistics, all at the Perelman School of Medicine of the University of Pennsylvania (Penn). He was honored as one of the Best Doctors in America, for each of his last eight years at Penn.
Dr. Strom earned a BS in Molecular Biophysics and Biochemistry from Yale University in 1971, and then an MD from the Johns Hopkins University School of Medicine in 1975. From 1975-78 he was an intern and resident in Internal Medicine and from 1978-80 he was an NIH fellow in Clinical Pharmacology at the University of California, San Francisco. He joined Penn’s faculty in 1980. The Center for Clinical Epidemiology and Biostatistics (CCEB) that he created at Penn includes over 550 faculty, research and support staff, and trainees. At the time Dr. Strom stepped down, CCEB research received nearly $49 million/year in extramural support, with a total budget of approximately $67 million.
Although Dr. Strom's interests span many areas of clinical epidemiology, his major research interest is in the field of pharmacoepidemiology, i.e., the application of epidemiologic methods to the study of drug use and effects. He is recognized as a founder of this field and for his pioneer work in using large automated databases for research. He is editor of the field's major text (now in its fifth edition) and Editor-in-Chief for Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology. As one of many specific contributions, his research was pivotal in prompting the American Heart Association and American Dental Association to reverse 50 years of guidelines, and recommend against use of antibiotics to prevent infective endocarditis, instead of recommending for this widespread practice. In addition to writing more than 650 papers and 15 books, he has been principal investigator for more than 275 grants, including over $115 million in direct costs alone. Dr. Strom has been invited to give more than 450 talks outside his local area, including presentations as the keynote speaker for numerous international meetings. He has been a consultant to NIH, FDA, CDC, USP, AAMC, JCAHO, foreign governments, most major pharmaceutical manufacturers, and many law firms.
Dr. Strom is also a nationally recognized leader in clinical research training. At Penn, Dr. Strom developed graduate training programs in epidemiology and biostatistics. More than 625 clinicians trained through the largest of these programs, which leads to a Master of Science in Clinical Epidemiology. All but approximately 65 have appointments in academic or other research institutions. Dr. Strom was PI or Co-PI of 11 different NIH-funded training grants (T32, D43, K12, and K30), each of which supported clinical epidemiology trainees in different specialties and subspecialties, and was the primary mentor for more than 40 clinical research trainees and numerous junior faculty members. Internationally, Dr. Strom was a key contributor to the conceptualization and planning that led to the development of the International Clinical Epidemiology Network (INCLEN), created in 1979 with support provided by the Rockefeller Foundation to provide clinical research training to clinicians from selected developing country sites. Penn was an INCLEN founding member and one of five training centers. INCLEN Phase I, from 1979 through 1995, resulted in the establishment of 26 clinical epidemiology units in Latin America, India, Africa, and Southeast Asia. The Penn training program alone, led by Dr. Strom, trained 63 INCLEN trainees.
Dr. Strom was a member of the Board of Regents of the American College of Physicians, the Board of Directors of the American Society for Clinical Pharmacology and Therapeutics, and the Board of Directors for the American College of Epidemiology, the Board of Directors for the Association for Patient-Oriented Research, and the Board of Directors of the Clinical Research Forum. He was previously President of the International Society for Pharmacoepidemiology and the Association for Clinical Research Training. Dr. Strom was on the Drug Utilization Review Committee and the Gerontology Committee of the United States Pharmacopoeia, served on the Drug Safety and Risk Management Advisory Committee for the US Food and Drug Administration, chaired the Institute of Medicine (IOM) (now the National Academy of Medicine) Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, chaired the IOM Committee on Smallpox Vaccine Program Implementation, chaired the IOM Committee to Review NIOSH’s Traumatic Injury Program, chaired the IOM Committee on the Consequences of Reducing Sodium in the Population, chaired the IOM Committee on a National Strategy for the Elimination of Hepatitis B and C and the Committee on Development of a Protocol to Evaluate the Concomitant Prescribing of Opioid and Benzodiazepine Medications and Veterans Deaths and Suicides. Dr. Strom was a member of the IOM Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and was a member of the IOM Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and the IOM Drug Forum.
Dr. Strom is a member of the American Epidemiology Society, and is one of a handful of clinical epidemiologists elected to the American Society of Clinical Investigation and American Association of Physicians. He has been an elected member of the IOM of the National Academy of Sciences (now National Academy of Medicine) since 2001. He received the 2003 Rawls-Palmer Progress in Medicine Award and the 2016 Oscar B. Hunter Career Award in Therapeutics from the American Society for Clinical Pharmacology & Therapeutics, the Naomi M. Kanof Clinical Investigator Award of the Society for Investigative Dermatology, and in 2006 he received the Sustained Scientific Excellence Award from the International Society for Pharmacoepidemiology. In addition, Dr. Strom was named the 2008 recipient of the John Phillips Memorial Award for Outstanding Work in Clinical Medicine. This award is from the American College of Physicians (ACP) and is considered to be one of the highest awards in Internal Medicine. Dr. Strom also received the 2013 Association for Clinical and Translational Science/American Federation for Medical Research National Award for Career Achievement and Contribution to Clinical and Translational Science for translation from clinical use into public benefit and policy. Penn awards that Dr. Strom received included the Class of 1992 Class Teaching Award and the Samuel Martin Health Evaluation Sciences Research Award. Dr. Strom received the 2004 Christian R. and Mary F. Lindback Award, the University’s most prestigious teaching award, in recognition of the contribution he has made in his career to clinical research teaching. The 2016 Oscar B. Hunter Career Award in Therapeutics was awarded to Dr. Strom for his outstanding contributions to clinical pharmacology and therapeutics. In 2017, Dr. Strom was named Honorary President of The Hellenic Society of Pharmacoepidemiology and in 2018 he was awarded an honorary doctorate from the University of Thrace in Greece. In 2020 he was named as a Fellow of the American Association for the Advancement of Science (AAAS).
Research
Dr. Strom’s major research interest is in the field of pharmacoepidemiology, the application of epidemiologic methods to the study of drug use and effects. He is recognized as a founder of this field and for his pioneering work in using large databases for research. He is editor of the field's major text (now in its sixth edition) and Editor-in-Chief for Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology
Professional service
Dr. Strom was a member of the Board of Regents of the American College of Physicians, the Board of Directors of the American Society for Clinical Pharmacology and Therapeutics, and the Board of Directors for the American College of Epidemiology, the Board of Directors for the Association for Patient-Oriented Research, and the Board of Directors of the Clinical Research Forum. He was previously President of the International Society for Pharmacoepidemiology and the Association for Clinical Research Training.
Dr. Strom was on the Drug Utilization Review Committee and the Gerontology Committee of the United States Pharmacopoeia, served on the Drug Safety and Risk Management Advisory Committee for the US Food and Drug Administration, chaired the Institute of Medicine (IOM) (now the National Academy of Medicine) Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, chaired the IOM Committee on Smallpox Vaccine Program Implementation, chaired the IOM Committee to Review NIOSH’s Traumatic Injury Program, chaired the IOM Committee on the Consequences of Reducing Sodium in the Population, chaired the IOM Committee on a National Strategy for the Elimination of Hepatitis B and C and the Committee on Development of a Protocol to Evaluate the Concomitant Prescribing of Opioid and Benzodiazepine Medications and Veterans Deaths and Suicides. Dr. Strom was a member of the IOM Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program, and was a member of the IOM Committee on Standards for Developing Trustworthy Clinical Practice Guidelines and the IOM Drug Forum.
Dr. Strom is a member of the American Epidemiology Society, and is one of a handful of clinical epidemiologists elected to the American Society of Clinical Investigation and American Association of Physicians. He has been an elected member of the IOM of the National Academy of Medicine since 2001. He received the 2003 Rawls-Palmer Progress in Medicine Award and the 2016 Oscar B. Hunter Career Award in Therapeutics from the American Society for Clinical Pharmacology & Therapeutics, the Naomi M. Kanof Clinical Investigator Award of the Society for Investigative Dermatology, and in 2006 he received the Sustained Scientific Excellence Award from the International Society for Pharmacoepidemiology. In addition, he was named the 2008 recipient of the John Phillips Memorial Award for Outstanding Work in Clinical Medicine. This award is from the American College of Physicians (ACP) and is considered to be one of the highest awards in Internal Medicine. Dr. Strom also received the 2013 Association for Clinical and Translational Science/American Federation for Medical Research National Award for Career Achievement and Contribution to Clinical and Translational Science for translation from clinical use into public benefit and policy. Penn awards that Dr. Strom received included the Class of 1992 Class Teaching Award and the Samuel Martin Health Evaluation Sciences Research Award. Dr. Strom received the 2004 Christian R. and Mary F. Lindback Award, the University’s most prestigious teaching award, in recognition of the contribution he has made in his career to clinical research teaching. The 2016 Oscar B. Hunter Career Award in Therapeutics was awarded to Dr. Strom for his outstanding contributions to clinical pharmacology and therapeutics. In 2017, Dr. Strom was named Honorary President of The Hellenic Society of Pharmacoepidemiology and in 2018 he was awarded an honorary doctorate from the University of Thrace in Greece. In 2020 he was named as a Fellow of the American Association for the Advancement of Science (AAAS).
Honors
His honors include:
- American College of Physicians’ John Phillips Memorial Award for Outstanding Work in Clinical Medicine
- The Naomi M. Kanof Clinical Investigator Award of the Society for Investigative Dermatology
- The International Society for Pharmacoepidemiology’s Sustained Scientific Excellence Award
- The National Award for Career Achievement and Contribution to Clinical and Translational Science from the Association for Clinical and Translational Science/American Federation for Medical Research
- The American Society of Clinical Pharmacology and Therapeutics’ Oscar B. Hunter Career Award in Therapeutics.
References
Books
1. Strom BL (ed). Pharmacoepidemiology. New York: Churchill Livingstone, 1989.
2. Strom BL, Velo GP (eds). Drug Epidemiology and Postmarketing Drug Surveillance. New York: Plenum Press, 1993.
3. Strom BL (ed). Pharmacoepidemiology (Second Edition). Sussex: John Wiley, 1994.
4. Strom BL (ed). Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000.
5. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL (eds). Committee to Assess the Safety and Efficacy of the Anthrax Vaccine, Medical Follow-up Agency. The Anthrax Vaccine: Is It Safe? Does It Work? Washington, DC: National Academy Press, 2002.
6. Strom BL (ed). Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005.
7. Committee on Smallpox Vaccination Program Implementation, Board on Health Promotion and Disease Prevention; Baciu A, Anason AP, Stratton K, Strom BL (eds). The Smallpox Vaccination Program: Public Health in an Age of Terrorism. Washington, DC: The National Academies Press, 2005.
8. Strom BL, Kimmel SE (eds). Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006.
9. Strom BL, Kimmel SE, Hennessy S (eds). Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012.
10. Strom BL, Yaktine AL, Oria M. Sodium Intake in Populations: Assessment of Evidence. Washington, DC: The National Academies Press, 2013.
11. Strom BL, Kimmel SE, Hennessy S (eds). Textbook of Pharmacoepidemiology (Second Edition). Chichester: JohnWiley, 2013.
12. Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population Health and Public Health Practice, Health and Medicine Division; Buckley GJ, Strom BL (eds). Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: The National Academies Press, 2016.
13. Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population Health and Public Health Practice, Health and Medicine Division; Buckley GJ, Strom BL (eds). Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase Two Report. Washington, DC: The National Academies Press, 2017.
14. Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons, 2019.
15. An Approach to Evaluate the Effects on Concomitant Prescribing of Opioids and Benzodiazepines on Veteran Deaths and Suicides. Strom BL, Bohnert AS, Gerhard T, Hernan M, King VL, Lewis R, Merlin J, Paddock S (eds). The National Academies Press, 2019.
Editorials, Reviews, Chapters, Letters to the Editor
1. Strom BL, Stolley PD, Brown TC. Antisubstitution law controversy-a solution? Annals of Internal Medicine 1974; 81:254-8
2. Strom BL, Melmon KL. Can post-marketing surveillance help to effect optimal drug therapy? Journal of the American Medical Association 1979; 242:2420-23.
3. Final Report of the Joint Commission on Prescription Drug Use, Washington: Joint Commission on Prescription Drug Use, 1980. (I wrote much of the body of the report for the Commission, functioning as a consultant.)
4. Strom BL, Miettinen OS, Melmon KL. Efficacy research on marketed drugs: issues of validity. Final Report of the Joint Commission on Prescription Drug Use. Washington, DC.: Joint Commission on Prescription Drug Use, 1980; Appendix VII.
5. Strom BL, Soloway RD. An association between gallstones and cancer. Gastroenterology 1981; 81:967-8.
6. Strom BL. Post-marketing drug surveillance: An idea whose time has come. In: Melmon KL, ed. Drug Therapeutics: Concepts for Physicians. New York: Elsevier-North Holland, 1982: 155-63.
7. Strom BL. Are estrogens effective in preventing fractures from post-menopausal osteoporosis? In: Melmon KL, ed. Drug Therapeutics: Concepts for Physicians. New York: Elsevier-North Holland, 1982:67-80.
8. Strom BL, Stolley PD, with the technical assistance of Hibberd P. Vascular and cardiac risks of steroidal contraception. Chapter 23 In: Sciarra JJ, ed. Gynecology and Obstetrics, Volume 6. Hagerstown, Maryland: Harper and Row, 1982:1-12.
9. Strom BL. Research projects. In: White KL, ed. Teaching clinicians epidemiology: problems and prospects. New York: The Rockefeller Foundation, 1982:101-2.
10. Strom BL. Teaching epidemiology to clinicians: an overall summary. In: White KL, ed. Teaching clinicians epidemiology: problems and prospects. New York: The Rockefeller Foundation, 1982:173.
11. Young MJ, Strom BL, Gibson GA, Barnathan ES, Coplan N. Naloxone-responsive hypotension in a patient with an ACTH-secreting tumor. Pharmacotherapy 1983; 3:342-3.
12. Sussman EJ, Strom BL, Soper KA. Exercise testing and prognosis in patients with atypical chest pain. International Journal of Cardiology 1983; 3:51-3.
13. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiologic Reviews 1983; 5:124-56.
14. Strom BL, Young MJ, Bresnitz EA. Nomograms for sample size. Letter to the editor. Annals of Internal Medicine 1983; 99:737-8.
15. Strom BL, Bresnitz EA. Sample-size nomograms. Letter to the editor. Annals of Internal Medicine 1983; 99:876.
16. Strom BL. Epidemiologic and biochemical aspects of an important sequel to cholelithiasis: gallbladder cancer. In: Capocaccia L, Ricci G, Angelico M, Attili AF, eds. Epidemiology and Prevention of Gallstones. Lancaster, Great Britain: MTP Press, Ltd., 1984; 64-76.
17. Strom BL, Nelson WL, Henson DE, Albores-Saavedra J, Soloway RD. Carcinoma of the gallbladder. In: Cohen S, Soloway RD, eds. Gallstones. New York: Churchill Livingstone, 1985:275-8.
18. Strom BL, West SL. The epidemiology of gallstone disease. In: Cohen S, Soloway RD, eds. Gallstones. New York: Churchill Livingstone, 1985:1-26.
19. Strom BL, Melmon KL, Miettinen OS. Postmarketing studies of drug efficacy. Archives of Internal Medicine 1985; 145:1791-4.
20. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clinical Pharmacology and Therapeutics 1986; 39:489-90.Morse ML, LeRoy AA, Strom BL. COMPASS®: A population-based postmarketing drug surveillance system. In: Inman WHW, ed. Monitoring for Drug Safety. Philadelphia: Lippincott, 1986; 237-54.
21. Carson JL, Strom BL. Techniques of postmarketing surveillance. An overview. Medical Toxicology 1986; 1:237-46.
22. Stolley PD, Strom BL. Evaluating and monitoring the safety and efficacy of drug therapy and surgery. Journal of Chronic Diseases 1986; 39:1145-55.
23. Strom BL. Medical databases in post-marketing drug surveillance. Trends in Pharmacological Sciences 1986; 7:377-80.
24. Strom BL. The promise of pharmacoepidemiology. Annual Review of Pharmacology and Toxicology 1987; 27:71-86.
25. Strom BL, West SL. Oral contraceptives and gallbladder disease. Clinical Pharmacology and Therapeutics 1987; 40:587-8.
26. Strom BL. Generic drug substitution – revisited. New England Journal of Medicine 1987; 316:1456-62.
27. Strom BL. Generic drugs. New England Journal of Medicine 1987; 317:1413.
28. Strom BL, Morse ML. Use of computerized databases to survey drug utilization in relation to diagnoses. Acta Medica Scandinavica 1988; Suppl 721:13-20.
29. Poungvarin N, Strom BL. Dexamethasone in primary supratentorial intracerebral hemorrhage. New England Journal of Medicine 1988; 318:255.
30. Strom BL. Overview of different logistical approaches to postmarketing surveillance. Journal of Rheumatology 1988; 15(Suppl 17):9-13.
31. Carson JL, Strom BL. The gastrointestinal side effects of the nonsteroidal anti-inflammatory drugs. Journal of Clinical Pharmacology 1988; 28:554-9.
32. Strom BL, West SL. Urinary tract infection and sexual activity. Annals of Internal Medicine 1988; 108:773-4.
33. Strom BL. Integrating pharmacoepidemiology into the design and conduct of clinical trials. Journal of Clinical Research and Drug Development 1988; 2:161-8.
34. Strom BL, Stolley PD. Vascular and cardiac risks of steroidal contraception. Chapter 23 In: Sciarra JJ, ed. Gynecology and Obstetrics, Volume 6. Hagerstown, Maryland: Harper and Row, 1989:1-17.
35. Strom BL. What is pharmacoepidemiology? Chapter 1 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989; 3-12.
36. Strom BL. Study designs available for pharmacoepidemiology studies. Chapter 2 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:13-26.
37. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:27-37.
38. Strom BL. When should one perform pharmacoepidemiology studies? Chapter 4 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:39-47.
39. Carson JL, Strom BL, Morse ML. Medicaid data bases. Chapter 14 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:173-88.
40. Strom BL. Other approaches to pharmacoepidemiology studies. Chapter 18 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:229-43.
41. Strom BL. How should one perform pharmacoepidemiology studies? Chapter 19 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:245-56.Carson JL, Strom BL, Maislin G. Screening for adverse drug reactions. Chapter 22 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:289-306.
42. Strom BL, Melmon KL. Using pharmacoepidemiology to study beneficial drug effects. Chapter 23 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:307-24.
43. Strom BL. The future of pharmacoepidemiology. Chapter 26 In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:363-9.
44. Strom BL. Sample size tables. Appendix A In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:373-406.
45. Strom BL. Glossary. Appendix B In: Strom BL, ed. Pharmacoepidemiology. New York: Churchill Livingstone, 1989:407-10.
46. Shusterman NH, Feldman HI, Wasserstein A, Strom BL. Reprocessing of hemodialyzers: a critical appraisal. American Journal of Kidney Disease 1989; 14:81 91.
47. Strom BL, Carson JL. Automated data bases used for pharmacoepidemiology research. Clinical Pharmacology and Therapeutics 1989; 46:390-4.
48. Stolley PD, Strom BL, Sartwell PE. Oral contraceptives and vascular disease. Epidemiologic Reviews 1989; 11:241-3.
49. Strom BL. Combining exposure and outcome data through record linkage. Proceedings of the WHO Anniversary Symposium: Adverse Drug Reactions – A Global Perspective on Signal Generation and Analysis. Uppsala: Almqvist and Wiksell Tryckeri, 1989; 49-50.
50. Strom BL, Carson JL. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding. Chapter 17 In: Edlavitch SA, ed. Pharmacoepidemiology, Volume 1. Chelsea, Michigan: Lewis Publishers, 1989; 229-41.
51. Strom BL, Taragin MI, Carson JL. Gastrointestinal bleeding from the nonsteroidal anti- inflammatory drugs. In: Weber E, Lawson DH, Hoigné R. eds. Risk Factors for Adverse
Drug Reactions – Epidemiological Approaches. Agents and Actions Supplement 1990; 29:27-38.
52. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, Shusterman NH, Strom BL. What is the cost of nephrotoxicity associated with aminoglycosides? Chapter 27 In: Edlavitch SA, ed. Pharmacoepidemiology, Volume 1. Chelsea, Michigan: Lewis Publishers, 1989; 333-52.
53. Strom BL, Gibson GA. What pharmacists should know about reporting adverse drug reactions. Wellcome Trends in Hospital Pharmacy 1990; 12:1-12.
54. Strom BL. The promise of pharmacoepidemiology: Comprehensive drug surveillance. Shimizu N, Tanaka Y, Jones J, Taylor D, eds. Improving Drug Safety: The Assessment, Management and Communication of the Therapeutic Benefits of Pharmaceutical Products. Japan: PharMa International 1990:54-61.
55. Strom BL, Tugwell P. Pharmacoepidemiology: current status, prospects, and problems. Annals of Internal Medicine 1990; 113:179-81.
56. Strom BL. US approach to detecting adverse drug effects. Compte Rendu du Colloque Les Effets Indesirables des Medicaments. Lyon: Marcel Merieux Foundation, 1990:19-22.
57. Strom BL, Carson JL. Medicaid billing data used to study the effects of marketed drugs. Journal of the Drug Information Association 1990; 24: 477-83.
58. Taragin MI, Carson JL, Strom BL. Gastrointestinal side effects of the nonsteroidal anti-inflammatory drugs. Digestive Diseases 1990; 8:269-80.
59. Strom BL, and members of the American Society for Clinical Pharmacology and Therapeutics - Pharmacoepidemiology Section. Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes. Clinical Pharmacology and Therapeutics 1990; 48:598.
60. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiologic Reviews 1990; 12:87-107.
61. Guess HA, Goldsmith CH, Henry D, Strom BL. Pharmacoepidemiology as a focus for clinical epidemiology in developing countries. Journal of Clinical Epidemiology 1991; 44 (Suppl II):101S-5S.
62. Feldman HI, Strom BL. Utilization of drugs for diabetes mellitus. Drug Safety 1991; 6:220-9.
63. Strom BL. Transesophageal echocardiography for endocarditis-associated abscesses. ACP Journal Club 1991; 115(Suppl 1):21.
64. Strom BL. Book review: Responsibility for drug-induced injury. Iatrogenics 1991; 1:38-9.
65. Strom BL. Methotrexate and liver fibrosis. A meta-analysis. ACP Journal Club 1991; 115(Suppl 2):61.
66. Strom BL. Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States. Annali dell' Instituto Superiore di Sanità (Annals of the National Health Institute of Italy) 1991; 27:235-237.
67. Carson JL, Strom BL. The gastrointestinal toxicity of the non-steroidal anti-inflammatory drugs. In: Rainsford KD and Velo GP. eds. Side Effects of Anti-Inflammatory Drugs 3,
Inflammation and Drug Therapy Series, Volume V. Boston: Kluwer Academic Publishers 1992:1-8.
68. Strom BL. Aspirin and Reye's syndrome. In: Rainsford KD and Velo GP, eds. Side Effects of Anti-Inflammatory Drugs 3, Inflammation and Drug Therapy Series, Volume V. Boston: Kluwer Academic Publishers 1992; 241-7.
69. Strom BL, Carson JL, Schinnar R, Snyder ES, West S. Nonsteroidal anti-inflammatory drugs and hypersensitivity reactions. In: Rainsford KD and Velo GP, eds. Side Effects of Anti-Inflammatory Drugs 3, Inflammation and Drug Therapy Series, Volume V. Boston: Kluwer Academic Publishers 1992:22-6.
70. Hennessy S, Strom BL. Issues in hospital-based drug use evaluation. P & T: A Peer-Reviewed Journal for Formulary Management 1992; 17:733-54.
71. Strom BL. A clinical epidemiology approach to therapeutics. In: Melmon KL, Morrelli H, Hoffman B, Nierenberg D, eds. Clinical Pharmacology (Third Edition). New York: Macmillan 1992:1022-8.
72. Strom BL. Pharmacoepidemiology studies using large databases. In: Strom BL, Velo GP. Drug Epidemiology and Postmarketing Drug Surveillance. New York: Plenum Press. 1992:65-71.
73. Carson JL, Strom BL. Screening for unknown effects of newly marketed drugs. In: Strom BL, Velo GP. Drug Epidemiology and Postmarketing Drug Surveillance. New York: Plenum Press. 1992:73-82.
74. Strom BL. Hospital-based adverse reaction and drug utilization review in the United States. In: Strom BL, Velo GP. Drug Epidemiology and Postmarketing Drug Surveillance. New York: Plenum Press. 1992; 99-101.
75. Kongpatanakul S, Strom BL. Quality of life, health status, and clinical drug research. PharmacoEconomics 1992; 2:8-14.
76. Gause KL, Nadzam DM, Vinson B, Strom BL. Development and use of the Joint Commission's adverse drug reaction indicator. P & T: A Peer-Reviewed Journal for Formulary Management 1992; 17:1517-33.
77. Strom BL. Review of Bert Spilker: Guide to clinical trials, Raven Press, 1991. Journal of Allergy and Clinical Immunology 1992; 90:868.
79. Rizzo JD, Strom BL, Berlin J. Replacement of central vascular catheters (letter; comment). New England Journal of Medicine 1993; 328:445-6.
78. Strom BL. Long-term outcome of native valve infective endocarditis. ACP Journal Club 1993; 118(Suppl 2):54.
79. Carson JL, Duff A, Strom BL. Drug-induced acute liver disease. Pharmacoepidemiology and Drug Safety 1993; 2:519-23.
80. Siegler EL, Strom BL. Pharmacoepidemiology: A tool to study adverse drug effects in the elderly. In: Developing Expertise in Geriatric Drug Therapy. Solicited chapter for a special publication by the Merck/AFAR Fellowship Program in Geriatric Clinical Pharmacology 1993:33-7.
81. Willett LR, Carson JL, Strom BL. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Safety 1994; 10:170-81.
82. Carson JL, Strom BL. Nonsteroidal antiinflammatory drugs. Chapter 81 In: Hazzard WR, et. al., eds. Principles of Geriatric Medicine and Gerontology (Third Edition). McGraw-Hill. 1994; 947-53.
83. Strom BL. What is pharmacoepidemiology? Chapter 1 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:3-13.
84. Strom BL. Study designs available for pharmacoepidemiology studies. Chapter 2 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:15-27.
85. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:29-38.
86. Strom BL. When should one perform pharmacoepidemiology studies? Chapter 5 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:57-65.
87. Carson JL, Strom BL, Morse ML. Medicaid data bases. Chapter 15 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:199-216.
88. Strom BL. Other approaches to pharmacoepidemiology studies. Chapter 23 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:323-35.
89. Strom BL. Choosing among the available approaches for pharmacoepidemiology studies. Chapter 24 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:337-50.
90. Carson JL, Strom BL, Maislin G. Screening for adverse drug reactions. Chapter 31 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:449-67.
91. Strom BL, Melmon KL. Using pharmacoepidemiology to study beneficial drug effects. Chapter 32 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:469-93.
92. West SL, Strom BL. Validity of pharmacoepidemiology drug and diagnosis data. Chapter 36 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:549-80.
93. Strom BL. The future of pharmacoepidemiology. Chapter 41 In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:649-55.
94. Strom BL. Sample size tables. Appendix A In: Strom BL . ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:659-92.
95. Strom BL. Glossary. Appendix In: Strom BL, ed. Pharmacoepidemiology (Second Edition). Chichester: John Wiley. 1994:693-9.
96. Strom BL. Adverse reactions to over-the-counter analgesics taken for therapeutic purposes. Journal of the American Medical Association 1994:272:1866-7.
97. O’Shea R, Strom BL, Berlin JA. Pancreatic cancer and diabetes. New England Journal of Medicine 1994; 331:1527.
98. Barrett TE, Strom BL. Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? American Journal of Respiratory and Critical Care Medicine 1995; 151:574-7.
99. Strom BL. Response to Keynote Address, Tenth ICPE – Pharmacoepidemiology: Response to the Challenge. Pharmacoepidemiology and Drug Safety 1995; 4:11-14.
100. Strom BL. Epidemiological methods for evaluating allergic reactions to drugs. In: Basomba A and Sastre J, eds. XVI European Congress of Allergology and Clinical Immunology, ECACI ‘95. Bologna, Italy: Monduzzi Editore 1995; 791-5.
101. Farrar JT, Strom BL. Drug utilization evaluation: Is big brother watching? Journal of General Internal Medicine 1995; 10:530-1.
102. Weinberg DS, Strom BL. Screening for colon cancer: a review of current and future strategies. Seminars in Oncology 1995; 22:433-47.
103. Strom BL. Cyclosporine plus methotrexate was superior to methotrexate alone for rheumatoid arthritis/ Prednisolone reduced the progression of early rheumatoid arthritis. ACP Journal Club 1996; 124:4-5.
104. Sekeres MA, Farrar JT, Strom BL. The J-curve interpreted: an alternative explanation of the results. Journal of General Internal Medicine 1996; 11:379-80.
105. Strom BL. What is the role of Departments of Internal Medicine in improving health care outcomes research? In: The Future Role of Subspecialists in Departments of Internal Medicine. DC: Association of Professors of Medicine. 1996; 97-106.
106. Strom BL, Berlin JA, Kinman JL, Hennessy S, Feldman H, Kimmel S, Carson JL. Risk of operative site bleeding from parenteral ketorolac. Journal of the American Medical Association 1996; 276:372.
107. Andrews EB, Avorn J, Bortnichak EA, Chen R, Dai WS, Dieck GS, Edlavitch S, Freiman J, Mitchell AA, Nelson RC, Neutel CI, Stergachis A, Strom BL, Walker AM. Guidelines for Good Epidemiology Practices for Drug, Device, and Vaccine Research in the United States. Pharmacoepidemiology and Drug Safety 1996; 5:333-8.
108. Strom BL, Kinman J, Berlin J, West S. Comments on “Risk factors for gallbladder cancer: an international collaborative case-control study.” Cancer 1996; 78:1516-7.
109. Strom BL. Research designs: multidisciplinary perspective. In: Influences of Sex and Gender on Health. Scientific Meeting and Public Hearing, Philadelphia: Agenda for Research on Women’s Health for the 21st Century. National Institutes of Health 1996:4:81-6.
110. Strom BL, Norman SA. Epidemiology of malignant disease. Chapter 24 In: Kelley WN, ed. Textbook of Internal Medicine (Third Edition). New York: J.B. Lippincott Company, 1997:138-41.
111. Strom BL. Principles of Clinical Epidemiology. Chapter 44 In: Kelley WN, ed. Textbook of Internal Medicine (Third Edition). New York: J.B. Lippincott Company, 1997:223-5.
112. Feldman HI, Kinman JL, Strom BL. Acute renal failure and ketorolac. Annals of Internal Medicine 1997; 127:493-4.
113. Strom BL. Study designs in pharmacoepidemiology. Encyclopedia of Biostatistics Chichester: John Wiley, 1998.
114. Mann RD, Strom BL. Revision of editorial policy. Pharmacoepidemiology and Drug Safety 1998; 7:309-10.
115. Carson JL, Strom BL. Use of nonsteroidal anti-inflammatory drugs. Chapter 83 In: Hazzard RH, et al., ed. Principles of Geriatric Medicine and Gerontology (Fourth Edition). New York: McGraw-Hill, 1998:1113-20.
116. Strom BL, Abrutyn E. Response to Jacobson, Adams, and Collignon. Annals of Internal Medicine 1999; 131:154-5.
117. Scotiniotis I, Lewis JD, Strom BL. Screening for colorectal cancer and other GI cancers. Current Opinion in Oncology 1999; 11:305-11.
118. Hennessy S, Strom BL. Nonsedating antihistamines should be preferred over sedating antihistamines in patients who drive. Annals of Internal Medicine 2000; 132:405-7.
119. Holmes EW, Burks, TF, Dzau V, Hindery MA, Jones RF, Kaye CI, Korn D, Limbird LE, Marchase RB, Perlmutter R, Sanfilippo F, Strom BL. Measuring contributions to the research mission of medical schools. Academic Medicine 2000; 75:303-13.
120. Strom BL. Sexual activity and cardiac risk: overview of epidemiologic research methods. American Journal of Cardiology, 2000; 86(2A):5F-9F.
121. Strom BL. Information about drugs: A clinical epidemiologic approach to therapeutics. Chapter 30 In: Carruthers GS, et al., ed. Melmon and Morrelli's Clinical Pharmacology: The Principles and Practical Application of Therapeutics (Fourth Edition). New York: McGraw-Hill, 2000:1329-39.
122. Strom BL. What is Pharmacoepidemiology? Chapter 1 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:3-15.
123. Strom BL. Study designs for pharmacoepidemiology studies. Chapter 2 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:17-29.
124. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:31-39.
125. Strom BL. When should one perform pharmacoepidemiology studies? Chapter 5 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:63-71.
126. Carson JL, Ray W, Strom BL. Medicaid databases. Chapter 19 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:307-324.
127. Strom BL. Other approaches to pharmacoepidemiologic studies. Chapter 24 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:387-399.
128. Strom BL. Choosing among the available approaches for pharmacoepidemiologic studies. Chapter 25 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:401-413.
129. Hennessy S, Strom BL, Soumerai SB, Lipton HL. Drug utilization review. Chapter 31 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:505-523.
130. Strom BL, Melmon KL. The use of pharmacoepidemiology to study beneficial drug effects. Chapter 34 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:553-572.
131. West SL, Strom BL. Validity of pharmacoepidemiology drug and diagnosis data. Chapter 39 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:661-705.
132. Strom BL, Norman S, Margolis DJ. Patient-oriented research: definitions and new paradigms. American Journal of Medicine 2000; 109:164-5.
133. Strom BL. The future of pharmacoepidemiology. Chapter 45 In: Strom BL, ed. Pharmacoepidemiology (Third Edition). Sussex: John Wiley, 2000:809-16.
134. Hennessy S, Strom BL. Statins and fracture risk. Journal of the American Medical Association 2001;285:1888-9.
135. Strom BL. When data conflict with practice: rethinking the use of prophylactic antibiotics before dental treatment. LDI Issue Brief 2001; 6:1-4.
136. Strom BL. Past, present, and future of pharmacoepidemiology. Bulletin of Osaka Pharmaceutical Manufacturers Association 2001; 13:26-41.
137. Strom BL. Comment: comparison of FDA reports of patient deaths associated with sildenafil and injectable alprostadil. Annals of Pharmacotherapy 2001; 35:1143.
138. Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA, Stallings VA, Drulis JM, Nelson SE, Hanson SA. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. Letter to the editor. Journal of the American Medical Association 2001; 286:2402-3.
139. Strom BL. Data validity issues in using claims data. Pharmacoepidemiology and Drug Safety 2001; 10:389-92.
140. Strom BL. Research in Complementary Therapies at the University of Pennsylvania. Education of Health Professionals in Complementary/Alternative Medicine. Phoenix Arizona: Josiah Macy, Jr. Foundation, 2001:143-6.
141. Kongpatanakul S, Strom BL. Pharmacoepidemiology and Drug Evaluation. Chapter 3 In: Van Boxtel CJ, Budiono S, Edwards IR, eds. Drug Benefits and Risks: International Textbook of Clinical Pharmacology. John Wiley & Sons, Ltd., 2001:27-36.
142. Chang JL, Freedman KB, Kaplan FS, Bilker WB, Strom BL, Lowe RA. Diagnostic bone-density testing. Letter to the editor. The Journal of Bone and Joint Surgery 2001:461-3.
143. Mann RD, Strom BL. The ISPE Pharmacoepidemiology and Drug Safety Best Paper Prize. Pharmacoepidemiology and Drug Safety 2002; 11:1.
144. Lewis JD, Strom BL. Balancing safety of dietary supplements with the free market. Annals of Internal Medicine 2002; 136:616-8.
145. Strom BL, Kinman JL. Overview of North American Databases. In: Mann RD, Andrews EB, eds. Pharmacovigilance. Chichester: England: Wiley, 2002:379-90.
146. Strom BL, Hennessy S. Pharmacist care and clinical outcomes for patients with reactive airways disease. Journal of the American Medical Association 2002; 288:1642-3.
147. Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL. Response to Drs. Kang and Majeed. American Journal of Gastroenterology 2003; 98:1896-7.
148. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Reply. Gastroenterology 2003; 1:390-1.
149. Strom BL, Mann RD. Journal’s policy regarding conflict of interest. Pharmacoepidemiology and Drug Safety 2003; 12:269-70.
150. Lewis JL, Strom BL. Principles of patient-based cancer research. Chapter 15 In: Rustgi AK, Crawford JM, eds. Gastrointestinal Cancer: a companion to Sleisenger and Fortrand's GI and liver disease. Philadelphia, PA: Saunders, 2003:185-92.
151. Strom BL. Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation: Letter Report #1. Institute of Medicine 2003; Available at: http://www.iom.edu/report.asp?id=4731.
152. Strom BL. Review of the Centers for Disease Control and Prevention's Smallpox Vaccination Program Implementation: Letter Report #2. Institute of Medicine 2003; Available at: http://www.iom.edu/report.asp?id=5379.
153. Strom BL. Review of the Centers for Disease Control and Prevention's Smallpox Vaccination Program Implementation: Letter Report #3. Institute of Medicine 2003; Available at: http://www.iom.edu/report.asp?id=11562.
154. Strom BL. Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation: Letter Report #4. Institute of Medicine 2003; Available at: http://www.iom.edu/report.asp?id=14631.
155. Strom BL. Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation: Letter Report #5. Institute of Medicine 2003; Available at: http://www.iom.edu/report.asp?id=17493.
156. Strom BL. Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation: Letter Report #6. Institute of Medicine 2004; Available at: http://www.iom.edu/report.asp?id=21243.
157. Gross R, Strom BL. Toward improved adverse event/suspected adverse drug reaction reporting. Pharmacoepidemiology and Drug Safety 2003; 12: 89-91.
158. Kimmel SE, Strom BL. Giving aspirin and ibuprofen after myocardial infarction. British Medical Journal 2003; 327:1298-9.
159. Hennessy S, Bilker WB, Weber A, Brensinger C, Strom BL. Retrospective drug utilization review, prescribing errors, and clinical outcomes. Journal of the American Medical Association 2004; 291:185-6.
160. Ness RB, Bondy ML, Branas C, Camargo CA, Rothenberg R, Samet JM, Sandler DP, Swanson M, Strom BL. Dissent is a cornerstone of scientific discourse. Annals of Epidemiology 2003; 13:597-8.
161. Strom BL, The Centers for Education & Research on Therapeutics (CERTs) Risk Assessment Workshop Participants. Risk assessment of drugs, biologics, and therapeutic devices: current approaches and future directions. Pharmacoepidemiology and Drug Safety 2003; 12:653-62.
162. Campbell WH, Califf RM for the Participants in the Centers for Education & Research on Therapeutics (CERTs) Risk Communication. Improving communication of drug risks to
prevent patient injury: proceedings of a workshop. Pharmacoepidemiology and Drug Safety 2003; 12:183-194.
163. Hennessy S, Strom BL. The ineffectiveness of retrospective drug utilization review. LDI Issue Brief 2003; 9:1-4.
164. Strom BL. What Are Our Drugs Truly Doing to Our Patients? Lessons From Pharmacoepidemiology. The John M. Eisenberg Memorial Lectureship on Therapeutics Research presented at: University of California, San Francisco. October 16, 2003; San Francisco, CA. Available at: http://www.chainonline.org/home/content_images/Eisenberg_UPENNCERT.pdf.
165. Strom BL, Schinnar R, Apter AJ. Cross-reactivity and sulfonamide antibiotics. New England Journal of Medicine 2004; 350:302-3.
166. Strom BL, Schinnar R. Letter to the editor. Mothering July/August 2004; Issue 125: Available at: http://www.mothering.com/10-0-0/html/10-6-0/soy-letters.shtml.
167. Halpern SD, Abrutyn E, Strom BL. Infective endocarditis. Chapter 4 In: Loeb M, Smieja M, Smaill F, eds. Evidence-Based Infectious Diseases. London: BMJ Books, 2004:37-51.
168. Strom BL. The potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. Journal of the American Medical Association 2004; 292:2643-6.
169. Strom BL. Evaluation of suspected adverse drug reactions. Letter to the editor. Journal of the American Medical Association 2005; 293:1324-5.
170. Strom BL. Statins and over-the-counter availability. New England Journal of Medicine 2005; 352:1403-5.
171. Koppel R, Metlay JP, Cohen A, Localio AR, Strom BL. Computerized Physician Order Entry Systems and Medication Errors. Reply. Journal of the American Medical Association 2005; 294:180-1.
172. Koppel R, Localio AR, Cohen A, Strom BL. Neither panacea nor black box: Responding to three Journal of Biomedical Informatics papers on computerized physician order entry systems. Journal of Biomedical Informatics 2005; 38:267-9.
173. Strom BL. What is pharmacoepidemiology. Chapter 1 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:3-15.
174. Strom BL. Overview of study designs available for pharmacoepidemiology studies. Chapter 2 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:17-28.
175. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:29-36.
176. Strom BL. When should one perform pharmacoepidemiology studies. Chapter 5 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:59-66.
177. Strom BL. Overview of automated databases in pharmacoepidemiology. Chapter 13 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:219-22.
178. Hennessy S, Carson JL, Ray WA, Strom BL. Medicaid databases. Chapter 18 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:281-94.
179. Strom BL. Other approaches to pharmacoepidemiology studies. Chapter 23 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:349-62.
180. Strom BL. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. Chapter 24 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:363-74.
181. Hennessy S, Soumerai SB, Lipton HL, Strom BL. Drug utilization review. Chapter 29 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:439-53.
182. Strom BL, Schinnar R. Hospital pharmacoepidemiology. Chapter 35 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:539-53.
183. Strom BL, Melmon KL (The Late). The use of pharmacoepidemiology to study beneficial drug effects. Chapter 40. In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:611-28.
184. West SL, Strom BL, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. Chapter 45 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:709-65.
185. Strom BL, Hennessy S. The future of pharmacoepidemiology. Chapter 49 In: Strom BL, ed. Pharmacoepidemiology (Fourth Edition). Sussex: John Wiley, 2005:833-39.
186. Andrews EB, Arellano FM, Avorn J, Bortnichak EA, Chen R, Dai WS, de Abajo FJ, Dieck GS, Edlavitch S, Freiman J, Jones JK, Kurz X, Lanes S, Mitchell AA, Nelson RC, Neutel I, Park B-J, Perez-Gutthann S, Stang P, Stergachis A, Strom BL, Trontell A, Walker AM, Waller P, West S.Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiology and Drug Safety 2005; 14:589-95.
187. CERTs Risk Communication and the Media Workshop Participants. The importance of news media in pharmaceutical risk communication: proceedings of a workshop. Pharmacoepidemiology and Drug Safety 2005; 14:297-306.
188. Centers for Education & Research on Therapeutics (CERTs) Workshop Participants. Managing the risks of therapeutic products: proceedings of a workshop. Pharmacoepidemiology and Drug Safety 2005; 14:619-28.
189. Apter AJ, Strom BL. Reacting to antibiotic allergies. LDI Issue Brief 2006; 11:1-4.
190. Strom BL. Role of public health and clinical medicine in preparing for disasters. In: Daniels RJ, Kettl DF, Kunreuther H, eds. On Risk and Disaster Lessons from Hurricane Katrina. Philadelphia, PA: University of Pennsylvania Press, 2006:231-41.
191. Strom BL. How the US drug safety system should be changed. Journal of the American Medical Association 2006; 295:2072-75.
192. Strom BL. Drug safety monitoring. Letter in Reply. Journal of the American Medical Association 2006; 296:1590.
193. Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. The FDA and drug safety: a proposal for sweeping changes. Archives of Internal Medicine 2006;166: 1938-42.
194. Strom BL. What is pharmacoepidemiology?. Chapter 1 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:3-11.
195. Strom BL. Study designs available for pharmacoepidemiology studies. Chapter 2 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:13-23.
196. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:25-33.
197. Strom BL. When should one perform pharmacoepidemiology studies? Chapter 5 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:55-62.
198. Strom BL. Overview of automated databases in pharmacoepidemiology. Chapter 11 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:167-171.
199. Strom BL. Other approaches to pharmacoepidemiology studies. Chapter 13 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:215-26.
200. Strom BL. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. Chapter 14 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:227-37.
201. West SL, Strom BL, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. Chapter 15 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:239-57.
202. Strom BL. The use of pharmacoepidemiology to study beneficial drug effects. Chapter 21 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:321-31.
203. Lee D, Majumdar SR, Lipton HL, Soumerai SB, Hennessy S, Davis RL, Chen RT, Bright RA, Mitchell AA, Graham DJ, Bates DW, Strom BL. Special applications of
pharmacoepidemiology. Chapter 27 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:397-442.
204. Strom BL, Kimmel SE. The future of pharmacoepidemiology. Chapter 28 In: Strom BL, Kimmel SE, eds., Textbook of Pharmacoepidemiology. Sussex: John Wiley, 2006:443-50.
205. Strom BL, Kinman JL. Overview of North American Databases. Chapter 28 In: Mann RD, Andrews EB, eds. Pharmacovigilance, (Second Edition). Chichester: England: Wiley, 2007:349-59.
206. Coogan P, Rosenberg, Strom BL. Response to letter: statins and cancer. Epidemiology 2007; 18:520-1.
207. Lo Re V III, Strom BL. The role of academia and the research community in assisting the Food and Drug Administration to ensure U.S. drug safety. Pharmacoepidemiology and Drug Safety 2007; 16:818-25.
208. Hennessy S, Strom BL. PDUFA reauthorization-drug safety’s golden moment of opportunity? New England Journal of Medicine 2007; 356:1703-4.
209. Mann R, Strom BL. Reporting adverse drug reactions. Pharmacoepidemiology and Drug Safety 2007; 16:473.
210. Strom BL, Lewis JD. In clarification. Author Reply. Pharmacoepidemiology and Drug Safety 2007; 16:1063-4.
211. Strom BL. Methodologic challenges to studying patient safety and comparative effectiveness. Medical Care 2007; 45:S13-5.
212. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Quality of Care and Outcomes Research Interdisciplinary Working Group. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Journal of the American Dental Association 2007; 138:739-45, 747-60.
213. Wilson W, Baddour LM, Baltimore RS, Bolger A, Bonow RO, Burns JC, Cabell CH, Durack DT, Ferrieri P, Gardner T, Gerber M, Gewitz M, Goff D, Levison M, Lockhart PB, Newburger JW, Pallasch T, Rowley AH, Shulman ST, Strom BL, Takahashi M, Tani LY, Taubert KA. Prevention of infective endocarditis guidelines from the American Heart Association. Letter to the Editor and Writing Group response. American Heart Association 2007; Available at: http://www.americanheart.org/presenter.jhtml?identifier=3048906.
214. Wilson W, Taubert KA, Gewitz M, Lockhart P, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Durack DT. Prevention of infective endocarditis. Guidelines from the American Heart Association. A guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736-54. Erratum in: Circulation 2007; 116:e376-7.
215. Califf RM, CERTs Benefit Assessment Workshop Participants. Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics. Pharmacoepidemiology and Drug Safety 2007; 16:5-16.
216. Lewis JD, Schinnar R, Bilker WB, Wang X. Strom BL. Response to van Staa and Parkinson. Pharmacoepidemiology and Drug Safety 2008; 17:104.
217. Andrews EB, Arellano FM, Avorn J, Bortnichak EA, Chen R, Dai WS, de Abajo FJ, Dieck GS, de Vries C, Edlavitch S, Freiman J, Jones JK, Koo L, Kaufman DW, Kurz X, Lanes S, Mitchell AA, Nelson RC, Neutel I, Park B-J, Perez-Gutthann S, Sacks S, Santanello N, Stang P, Stergachis A, Strom BL, Trontell A, Walker AM, Waller P, Watson DJ, West S, Wilcock K, Wise RP. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiology and Drug Safety 2008; 17:200-208.
218. Rebbeck TR, Troxel AB, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin JA, Strom BL. Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Erratum in: American Journal of Epidemiology 2008; 167:888.
219. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, Bolger A, Cabell CH, Takahashi M, Baltimore RS, Newburger JW, Strom BL, Tani LY, Gerber M, Bonow RO, Pallasch T, Shulman ST, Rowley AH, Burns JC, Ferrieri P, Gardner T, Goff D, Curack DT; American Heart Association. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Journal of the American Dental Association 2008; 139 (Suppl):3S-24S. Review. Erratum in: Journal of the American Dental Association 2008; 139:253.
220. Strom BL. Comparative effectiveness of β-blockers in elderly patients with heart failure-Invited commentary. Archives of Internal Medicine 2008; 168:2428-2431.
221. Kongpatanakul S, Strom BL. Pharmacoepidemiology and drug evaluation. Chapter 3 In: von Boxtel CJ, Santoso B, Edwards IR, eds. Drug Benefits and Risks: International Textbook of Clinical Pharmacology (Revised Second Edition) 2008: 27-36.
222. Strom BL. Regional editor sought for Pharmacoepidemiology and Drug Safety for the Asia-Pacific region, Middle East and Africa. Pharmacoepidemiology and Drug Safety 2009; 18:1252.
223. Strom BL. A new hand on the rudder. Pharmacoepidemiology and Drug Safety 2009; 18:982.
224. Zhang Y, Coogan PF, Strom BL, Rosenberg L. Response to Dr. Costellos' submission entitled "Re: Vitamin and mineral use and risk of prostate cancer: the case-control surveillance: Zhang et al. Cancer Causes Control 2009 ; 20:691-8.
225. Halpern SD, Abrutyn E, Strom BL. Infective endocarditis. Chapter 4. In: Loeb M, Smieja M, Smaill F, eds. Evidence-Based Infectious Diseases (Second Edition). London: BMJ Books, 2009: 42-54.
226. Keefe SM, Strom BL. On the importance of heterogeneity in meta-analysis. Clinical Trials 2009; 6:443-4.
227. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. Response to Dr. Shapiro: Oral contraceptives and risk of breast cancer. American Journal of Epidemiology 2009; 170:803-4.
228. Strom BL, Kinman JL. Changes in the life of PDS – The start of a new phase. Pharmacoepidemiology and Drug Safety 2010; 19:771-4.
229. Leonard CE, Freeman CP, Deo R, Newcomb C, Kimmel SE, Strom BL, Bilker WB, Hennessy S. Response to commentary entitled ‘Commentary on the validation studies of sudden cardiac death and ventribular arrhythmia by Hennessy et al. and Chung et al.’ Pharmacoepidemiology and Drug Safety 2010; 19:576.
230. Selker HP, Strom BL, Ford DE, Meltzer DO, Pauker SG, Pincus HA, Rich EC,Tompkins C, Whitlock EP. White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research. Clinical and Translational Science 2010; 3:29-37.
231. Strom BL, Schinnar R, Aberra F, Bilker W, Hennessy S, Leonard CE. Hard-stops for drug interactions. Letter in Reply. Archives of Internal Medicine 2011; 171:706.
232. Strom BL. Response to Vieweg and Hasnain letter on behalf of the Zodiac investigators. American Journal of Psychiatry 2011; 168:6.
233. Strom BL, Kelly TO, Landis JR, Feldman HI. The Center for Clinical Epidemiology and Biostatistics of the Perelman School of Medicine at the University of Pennsylvania: an organizational model for clinical research in a school of medicine. Academic Medicine 2012; 87:60-65.
234. Strom BL, Kelly TO, Norman SA, Farrar JT, Kimmel SE, Lautenbach E, Feldman HI. The Master of Science in Clinical Epidemiology degree program of the Perelman School of Medicine at the University of Pennsylvania: a model for clinical research training. Academic Medicine 2012; 87:74-80.
235. Strom BL. What is pharmacoepidemiology? Chapter 1 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 3-22.
236. Strom BL. Basic principles of clinical epidemiology relevant to pharmacoepidemiologic studies. Chapter 3 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 38-51.
237. Strom BL. Sample size considerations for pharmacoepidemiologic studies. Chapter 4 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 52-61.
238. Strom BL. When should one perform pharmacoepidemiologic studies? Chapter 5 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 62-71.
239. Strom BL. Overview of automated databases in pharmacoepidemiology. Chapter 11 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 158-62
240. Strom BL. How should one perform pharmacoepidemiologic studies? Choosing among the available alternatives. Chapter 23 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 364-78.
241. Strom BL, Schinnar R, Hennessy S. Comparative effectiveness research. Chapter 32 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 561-82.
242. Strom BL, Melmon KL (The Late). The use of pharmacoepidemiology to study beneficial drug effects. Chapter 37 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 655-77.
243. Strom BL, Kimmel SE, Hennessy S. The future of pharmacoepidemiology. Chapter 48 In: Strom BL, Kimmel SE, Hennessy S, eds., Pharmacoepidemiology (Fifth Edition). Sussex: John Wiley 2012: 895-903.
244. Habel L, Ferrara A, Bilker WB, Quesenberry CP, Selby JV, Van Den Eeden SK, Strom BL, Lewis JD. Response to the analyses using time-dependent pioglitazone usage in Cox models may lead to wrong conclusions about its association with cancer. Diabetes Care 2011; 34:e136.
245. Hornbrook M, Pope J, Vandermeer M, Rumptz M, Bates D, Strom BL Woosley, R, Lambert B. Focus on Patient Safety, Spotlight on CERTs Research: Health IT and Patient Safety. Focus on Patient Safety 2012; 1: 1-2, 5-6.
246. Strom BL, Anderson CAM, Ix JH. Sodium reduction in populations: insights from the Institute of Medicine committee. Journal of the American Medical Association 2013; 310:31-2. doi:10.1001/jama.2013.7687.
247. Strom BL. What is pharmacoepidemiology? Chapter 1 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology (Second Edition). Chichester: John Wiley 2013: 3-16.
248. Strom BL. Study designs available for pharmacoepidemiology studies. Chapter 2 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology (Second Edition). Chichester: John Wiley 2013: 17-29.
249. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology (Second Edition). Chichester: John Wiley 2013: 30-39.
250. Strom BL. When should one perform pharmacoepidemiology studies? Chapter 5 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology (Second Edition). Chichester: John Wiley 2013: 54-62.
251. Strom BL. Overview of automated databases in pharmacoepidemiology. Chapter 8 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology. (Second Edition) Chichester: John Wiley 2013: 118-22.
252. Strom BL. How should one perform pharmacoepidemiology studies? Choosing among the available alternatives. Chapter 11 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology. (Second Edition) Chichester: John Wiley 2013: 190-202.
253. Lee D, Majumdar SR, Lipton HL, Soumerai SB, Hennessy S, Davis RL, Chen RT, Bright RA, Mitchell AA, Graham DJ, Bates DW, Strom BL. Special applications of pharmacoepidemiology. Chapter 22 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology. (Second Edition) Chichester: John Wiley 2013: 339-406.
254. Strom BL, Kimmel SE. The future of pharmacoepidemiology. Chapter 23 In: Strom BL, Kimmel SE, Hennessy SH, eds., Textbook of Pharmacoepidemiology. (Second Edition) Chichester: John Wiley 2013: 407-15.
255. Gross R, Bellamy SL, Strom BL. Letter to the Editor, Journal of the American Medical Association - Internal Medicine 2013; 173: 1475-6.
256. Strom BL, Hasford J, Hennessy S, Park BJ, Kinman JL. In memoriam: Ronald D. Mann, MD, FRCP, FRCGP, FFPM, FISPE, Professor Emeritus, Honorary Lifetime ISPE Fellow, 1928-2013: Perspectives of ISPE’s Founding Executive Director. Pharmacoepidemiology and Drug Safety 2014; 23:558-9.
257. Strom BL, Buyse M, Hughes J, Knoppers BM. Data sharing, year 1 – Access to data from industry-sponsored clinical trials. New England Journal of Medicine 2014; 371:2052-4.
258. Hennessy S, Strom BL. Improving postapproval drug safety surveillance: getting better information sooner. Annual Review of Pharmacology and Toxicology 2015; 55:75-87.
259. Lo Re V 3rd, Forde KA, Lewis JD, Goldberg DS, Carbonari DM, Roy J, Reddy KR, Sha D, Strom BL, Corley DA. Reply. Clinical Gastroenterology and Hepatology 2016; 918-9.
260. Strom BL, Hennessy S, Park BJ, Kinman JL. Transition in the Office of Regional Editor for Europe. Pharmacoepidemiology and Drug Safety 2016; 25:1.
261. Andrews EB, Arellano FM, Avorn J, Bortnichak EA, Chen R, Dai WS, de Abajo FJ, Dieck GS, de Vries C, Edlavitch S, Freiman J, Hallas J, Jones J, Koo L, Kaufman DW, Kurz X, Lanes S, Mitchell AA, Moride Y, Nelson RC, Neutel I, Park BJ, Perez-Gutthann S, Reynolds R, Sacks S, Santanello N, Stang P, Stergachis A, Strom BL, Stürmer T, Toh D, Trontell A, Walker AM, Waller P, Watson DJ, West S, Wilcock K, Wise RP. Guidelines for good pharmacoepidemiology practice (GPP). Public Policy Committee, Pharmacoepidemiology and Drug Safety 2016; 25:2-10.
262. Buckley GJ, Strom BL. What stands in the way of making hepatitis B and C rare diseases in the United States? Annals of Internal Medicine 2016; 112:284-5.
263. Strom BL, Buyse M, Hughes J, Knoppers BM. Data sharing: Is the juice worth the squeeze? New England Journal of Medicine 2016; 375:1608-9.
264. Buckley GJ, Strom BL. A national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C. Annals of Internal Medicine 2017; 166:895-896.
265. Strom BL. Endings and beginnings. Pharmacoepidemiology and Drug Safety 2018; 27:1-2.
266. Sood N, Ung D, Shankar A, Strom BL. A novel strategy for increasing access to treatment for hepatitis C virus infection for Medicaid beneficiaries. Annals of Internal Medicine 2018. [Epub ahead of print]. doi:10.7326/M18-0168.
267. Sood N, Shankar A, Strom BL. A novel strategy for increasing access to treatment for Hepatitis C virus infection or Medicaid beneficiaries. Annals of Internal Medicine 2018; 169:118-9.
268. Strom BL. What is pharmacoepidemiology? Chapter 1 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 3-26.
269. Strom BL. Sample size considerations for pharmacoepidemiology studies. Chapter 3 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 44-59.
270. Strom BL. Sample Size Considerations for Pharmacoepidemiologic Studies. Chapter 4 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 60-70.
271. Strom BL. When Should One Perform Pharmacoepidemiologic Studies? Chapter 5 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 71-80.
272. Strom BL. Overview of Electronic Databases in Pharmacoepidemiology. Chapter 11 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 205-10.
273. Strom BL. Choosing Among the Available Data Sources for Pharmacoepidemiology Research. Chapter 17 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 357-71.
274. Strom BL. The Use of Pharmacoepidemiology to Study Beneficial Drug Effects. Chapter 33 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 813-36.
275. Strom BL. The Future of Pharmacoepidemiology. Chapter 44 In: Strom BL, Kimmel SE, Hennessy SH (eds). Pharmacoepidemiology (Sixth Edition). John Wiley and Sons 2019: 1111-22.
276. Blaser M, Strom BL, Bello MGD. Is antibiotic prophylaxis justified for operative vaginal delivery? The Lancet 2020: 188.
277. Gigliotti R, Ruben B, Goldthwaite C, Strom BL. The collaborative design of a leadership education and development program for an academic health center: implications for leadership education practice. International Journal of Leadership in Education, 2020; https://doi.org/10.1080/13603124.2020.1823487.
278. Eyal N, Gerhard T, Strom BL. When efficacy overrides safety: Can SARS-Cov-2 vaccine evaluation be complete in the community? Submitted for publication.
279. Lamba S, Omary MB, Strom BL. Diversity, Equity, Inclusion, and Belonging: an institutional certainty for the uncertain era of COVID-19. Submitted for publication.
280. Gerhard T, Strom BL, Eyal N. Parallel SARS-CoV-2 vaccine testing—combining conventional and challenge studies (CCC). Submitted for publication.
281. Eyal N, Gerhard T, Strom BL. Strengthening and accelerating SARS-CoV-2 vaccine safety testing through registered pre-marketing rollout. Submitted for publication.Template:Rutgers Biomedical